More importantly, genes important for lymphocyte activation (Cd69 and Klrk1) were upregulated in tumors treated with AMDs(i.v.)+light (Figure 7D).[31] Anti‐tumor effector genes (Ifng, Gzma, Gzmb, and Fasl) were also upregulated in tumors treated with AMDs(i.v.)+light (Figure 7E),[32] whereas the protumoral or immunosuppressive genes Csf1, Vegfa, Arg1, Cd274 (encoding PD‐L1), and Pdcd1lg2 (encoding PD‐L2) were downregulated to varying degrees (Figure S10, Supporting Information).[30, 31, 32, 33] These immunological changes confirmed the potent antitumor effects of AMDs(i.v.)+light treatment. The gene discussed is GZMA; the disease is neoplasm.